CA2614529C — Pyridazinone derivatives as thyroid hormone receptor agonists
Assigned to F Hoffmann La Roche AG · Expires 2011-06-28 · 15y expired
What this patent protects
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the sub-stituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of di…
USPTO Abstract
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the sub-stituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholes-terolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, car-diovascular diseases, hypothyroidism, thyroid cancer and other disor-ders and diseases related thereto.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.